Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR., Belij-Rammerstorfer S., Dold C., Ewer KJ., Folegatti PM., Gilbride C., Halkerston R., Hill J., Jenkin D., Stockdale L., Verheul MK., Aley PK., Angus B., Bellamy D., Berrie E., Bibi S., Bittaye M., Carroll MW., Cavell B., Clutterbuck EA., Edwards N., Flaxman A., Fuskova M., Gorringe A., Hallis B., Kerridge S., Lawrie AM., Linder A., Liu X., Madhavan M., Makinson R., Mellors J., Minassian A., Moore M., Mujadidi Y., Plested E., Poulton I., Ramasamy MN., Robinson H., Rollier CS., Song R., Snape MD., Tarrant R., Taylor S., Thomas KM., Voysey M., Watson MEE., Wright D., Douglas AD., Green CM., Hill AVS., Lambe T., Gilbert S., Pollard AJ., Oxford COVID Vaccine Trial Group .

DOI

10.1038/s41591-021-01372-z

Type

Journal article

Publication Date

2021-06-01T00:00:00+00:00

Volume

27

Permalink More information Close